Docetaxel 2-weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer
A Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety of a Single Agent Docetaxel 2-Weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer to a 3-Weeks Regimen
Breast Cancer
DRUG: Docetaxel
Progression-free survival(PFS), Progression-free survival (PFS) is defined as the time elapsed between enrolling and tumor progression or death from any cause, From date of enrolling until the date of first documented progression or date of death from any cause, whichever came first,assessed up to 5 years
Overall survival(OS), The time elapsed between enrolling and death from any cause, From date of enrolling until the date of death from any cause, assessed up to 5 years|Clinical benefit rate(CBR), The response is CR+PR+SD ≥ 24 weeks, From date of enrolling until the date of first documented progression or date of death from any cause, whichever came first,assessed up to 5 years|Quality of life（QOL）, Score change from enrolling to progression disease or death according EORTC QLQ-C30.The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients., From date of enrolling until the date of first documented progression or date of death from any cause, whichever came first，assessed up to 5 years|Number of participants with Grade 3/4 adverse events, Number of participants with Grade 3/4 adverse events of the two groups was assessed in accordance with the common terminology criteria (NCI CTC AE) version 4.0., From date of enrolling until the date of 1 month of stop treatment, assessed up to 5 years
Docetaxel 2-Weeks Regimen:Docetaxel 50mg/m2 Docetaxel 3-Weeks Regimen:Docetaxel 75mg/m2